Ask AI

Lymphoma and Leukemia

For coverage of gastrointestinal, lung, and breast cancers at ASCO 2026, click here.

Share

Program Content

Activities

  • frontMIND
    frontMIND: Phase III Trial of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP for Newly Diagnosed DLBCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 23, 2026

  • BRUIN CLL 313 314 Pooled Analysis
    BRUIN CLL-313 and BRUIN CLL-314: A Pooled Analysis of Pirtobrutinib in Previously Untreated CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 24, 2026

  • CLL14
    CLL14: Final Analysis of Phase III Study of First-line Venetoclax + Obinutuzumab for CLL 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 24, 2026

  • BRUIN CLL 322
    BRUIN CLL-322: Phase III Trial of Fixed-Duration Pirtobrutinib + Venetoclax/Rituximab vs Venetoclax/Rituximab in Previously Treated CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 25, 2026

  • SOUNDTRACK F1
    SOUNDTRACK-F1: Initial Safety and Efficacy From a Phase III Trial of First-line Surovatamig + Rituximab for Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 26, 2026

  • Sonrotoclax Plus Zanubrutinib in TN CLL
    Sonrotoclax + Zanubrutinib in Treatment-Naive CLL/SLL: A Phase I Study
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 26, 2026

  • AJX 101
    AJX-101: Phase I Study of AJ1-11095, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis After Prior Type I JAK2 Inhibitor Treatment
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 26, 2026

  • ASC4FIRST Wk 144 Update
    ASC4FIRST: Wk 144 Update of Asciminib vs Investigator-Selected TKI in Newly Diagnosed CML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2026

  • EPO-PRETAR
    EPO-PRETAR: Final Results With Early vs Delayed Erythropoiesis-Stimulating Agent Initiation in Nontransfusion-Dependent Patients With Lower-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 30, 2026

  • OPTI-AML
    OPTI-AML: Phase II Trial of 28-Day vs 14-Day Venetoclax and Azacitidine for 2 Cycles in Patients Aged ≥60 Years with Newly Diagnosed Genomically Agnostic AML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 01, 2026

  • SENTRY
    SENTRY: Phase III Study of Selinexor + Ruxolitinib in Patients With JAK Inhibitor–Naive Myelofibrosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 02, 2026

  • KOMET 007
    KOMET-007: Long-term Results From the Phase I Trial of Ziftomenib Plus 7 + 3 Intensive Induction Therapy in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 06, 2026

  • CaDAnCe 101 CLL
    CaDAnCe-101: Update From a Phase I Study of BTK Degrader Tacabrutideg (BGB-16673) in R/R CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 07, 2026

  • MAXILUS
    MAXILUS: Primary Analysis of the Phase III Trial of Luspatercept Initiation at Maximum-Approved Dose in Patients With Lower-Risk MDS Requiring Transfusions
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 08, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation